. Author manuscript; available in PMC: 2019 Sep 1.

Published in final edited form as: Am J Transplant. 2018 Jun 27;18(9):2189–2199. doi: 10.1111/ajt.14933

TABLE 2.

Primary and secondary outcomes

	Subclinical inflammation (n = 37)
	B-TCMR (n = 24)	SC-TCMR (n = 13)	Total (n = 37)	NOMOA (n = 66)	P-value
Composite endpoint (no., %)	13 (54%)	6 (46%)	19 (51%)	11 (17%)	<.001
Acute rejection, postsurveil- lance (no., %)	13 (54%)	5 (39%)	18 (49%)	11 (17%)	.001
Death-censored graft loss (no., %)	3 (13%)	2 (15%)	5 (14%)	4 (6%)	.20
Early rejection (<1 y)/late rejection (1–5 y)	6/7	5/0	11/7	5/6	.47
Estimated GFR at 1 y (mL/min/1.73 m²)	61 ± 25	79 ± 37	67 ± 30	74 ± 34	.35
eGFR at last follow-up (mL/min/1.73 m²)	48 ± 25	63 ± 36	53 ± 29	58 ± 22	.36
Annualized change in eGFR (mL/min/1.73 m²/y)	−10.04	−8.31	−9.46	−8.57	.85

The primary outcome is a 5-year composite endpoint of acute rejection after surveillance and death-censored graft failure. The P-value represents the comparison between the subclinical inflammation and no major abnormalities groups, with significant values noted in bold type.

B-TCMR, borderline T cell–mediated rejection; NOMOA, no major abnormalities; SC-TCMR, subclinical T cell–mediated rejection.